Item 2.02 Results of Operations and Financial Condition.

On January 11, 2022, NeuroPace, Inc. ("NeuroPace") issued a press release announcing its preliminary financial results for the fiscal quarter and year ended December 31, 2021 and business highlights. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

NeuroPace has prepared an investor presentation for use at the J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. Eastern Time. A copy of the investor presentation is attached hereto as Exhibit 99.2 and is incorporated into this Item 7.01 by reference. A copy of the investor presentation will also be accessible on the Company's website at https://investors.neuropace.com/news-and-events/presentations.

The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.




Exhibit
  No.       Description

99.1          Press release dated January 11, 2022

99.2          Investor presentation dated January 11, 2022

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses